Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases.
A 43-yr-old-man with metastatic VIPoma in whom the conventional measures of surgery, chemotheraphy, and hepatic artery embolization ultimately failed to control his severe diarrhea, resulting from vasoactive intestinal polypeptide hypersecretion, was treated with a new long-acting somatostatin analogue, SMS 201-995, for 14 mo. SMS 201-995 not only controlled the diarrhea without side effects but appeared to have possibly induced a reduction in metastatic tumor size.
Kraenzlin
M E
ME
Ch'ng
J L
JL
Wood
S M
SM
Carr
D H
DH
Bloom
S R
SR
D007516:Adenoma, Islet Cell / Q000188:drug therapy*; D000328:Adult; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D008297:Male; D015282:Octreotide; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D014660:Vasoactive Intestinal Peptide / Q000097:blood; D003969:Vipoma / Q000188:drug therapy* / Q000473:pathology
D003692:Delayed-Action Preparations; D014660:Vasoactive Intestinal Peptide; D013004:Somatostatin; D015282:Octreotide